Literature DB >> 8547152

Effects of different amino-acid substitutions in the leucine 694-proline 708 segment of recombinant von Willebrand factor.

L Hilbert1, C Gaucher, C Mazurier.   

Abstract

Type 2B von Willebrand disease (vWD) is characterized by an increased affinity of von Willebrand factor (vWF) for binding to platelet glycoprotein Ib (GpIb). Most type 2B candidate mutations are clustered in the 509-695 disulphide loop but three of them (H505D, L697V and A698V) are outside this loop. We confirm here that the A698V mutation is a type 2B mutation by its expression in Cos-7 cells. As the L697V and A698V type 2B mutations both induce the presence of a valine residue in the 694-708 sequence, we created and expressed different mutated recombinant vWFs (rvWFs), in substituting the other leucine and alanine residues of this sequence (at positions 694, 701 and 706) into valine resides. V694rvWF and V706rvWF displayed decreased ristocetin-induced GpIb binding showing that it is not always the presence of a valine residue that may explain the increased affinity of type 2B vWF for GpIb. We also compared the interaction with platelets of V697rvWF and V698rvWF to those obtained with rvWFs reproducing two prevalent type 2B mutations located in the loop (R543W and V553M). We show that the two mutations located in the loop are more reactive than the two mutations identified outside the loop.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547152     DOI: 10.1111/j.1365-2141.1995.tb05423.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

Review 1.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor.

Authors:  W Deng; Y Wang; S A Druzak; J F Healey; A K Syed; P Lollar; R Li
Journal:  J Thromb Haemost       Date:  2017-08-09       Impact factor: 5.824

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.